The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).
 
Emmanuel Seront
No Relationships to Disclose
 
Sylvie Rottey
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer
Research Funding - Bayer (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Pfizer
 
Bertrand Filleul
No Relationships to Disclose
 
Phillipe Glorieux
No Relationships to Disclose
 
Jean Charles. Goeminne
No Relationships to Disclose
 
Jean-Marie Vandenbulcke
No Relationships to Disclose
 
Brieuc Sautois
No Relationships to Disclose
 
Petra Boegner
No Relationships to Disclose
 
Vincent Verschaeve
No Relationships to Disclose
 
Aline Gillain
No Relationships to Disclose
 
Aline Van Maanen
No Relationships to Disclose
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - Boehringer Ingelheim; Merck Sharp & Dohme; Pfizer
Research Funding - Bayer; Novartis; Sanofi